Adenoid Cystic Carcinoma

Types
Causes
Symptoms and signs
Diagnostic tests
Non-pharmacological treatments
Drug treatments
Dietary “molecular/supportive” supplements
Immunity-booster / regenerative / stem-cell” drugs
Surgeries
Prevention & self-care pointers
When to see doctors
What to eat & “what to avoid
FAQs

Adenoid Cystic Carcinoma (ACC) is a slow-growing but stubborn cancer that most often starts in the salivary glands (parotid, submandibular, minor glands of the mouth, nasal cavity, or sinuses). It tends to grow along nerves (called perineural spread) and can return years later or spread to the lungs, bone, or liver. The mainstays of care are surgery to remove all visible tumor when possible, plus post-operative radiotherapy to lower the risk of local return. Systemic (whole-body) medicines can help in advanced or metastatic disease, but response rates are modest; targeted drugs like lenvatinib and axitinib are the most consistently active options so far, while immunotherapy works only for a minority. Particle radiotherapy (proton or carbon-ion) is used in select centers for complex skull-base or sinonasal disease. PMC+2PMC+2NCCN

Adenoid cystic carcinoma is a cancer that starts from gland cells that make saliva or similar secretions. Under the microscope, doctors see special patterns (cribriform, tubular, or solid). ACC grows slowly at first, but it can travel along the tiny tunnels that carry nerves. This “perineural” travel can bring the tumor to the base of the skull or into the brain’s lining. Even after good early treatment, ACC can come back locally or show up in distant places—most often the lungs—many years later. Because of this behavior, treatment plans focus on clean surgical removal when possible, meticulous radiation planning to sterilize nerve pathways at risk, and long-term follow-up. Modern studies also show that ACC often carries a MYB::NFIB or MYBL1::NFIB gene fusion that drives the tumor, and a subset has changes in the NOTCH pathway—findings that are shaping clinical trials and targeted therapy choices. PMC+1Lippincott JournalsFrontiers

Adenoid cystic carcinoma (ACC) is a rare cancer that begins most often in the small saliva-making glands of the head and neck. These glands sit in the lips, palate, tongue, cheeks, sinuses, and around the jaw. ACC can also start in glands that make similar fluids in other places, such as the windpipe, lungs, breast, tear gland, or skin. ACC usually grows slowly, but it behaves in a special way: it tends to track along nerves (called “perineural spread”) and can come back many years after first treatment. It can also travel to the lungs or bones. Under the microscope, doctors see patterns called cribriform, tubular, or solid. The first two patterns act more gently; the solid pattern acts more aggressively. ACC does not usually enlarge nearby lymph nodes, so nodes can look normal even when cancer is present elsewhere. Because ACC grows along nerves and into hidden spaces, imaging and biopsy are very important to map its true size and reach. Treatment is usually surgery with careful removal of tissue around the tumor, followed by radiation. Medicines are used when disease has spread or cannot be fully removed. Even when cured locally, ACC needs very long follow-up because it can return late.

Other names

Adenoid cystic carcinoma is also called ACC, cylindroma (older term), cribriform carcinoma of the salivary glands, or adenocystic carcinoma. When it arises outside salivary glands, clinicians may add the site, such as lacrimal gland ACC, tracheal ACC, breast ACC, or skin adnexal ACC. All share similar microscopic patterns (cribriform, tubular, solid) and a tendency for perineural spread.

Types

1) By histologic pattern (what the microscope shows)

Cribriform type: The classic “Swiss-cheese” look with round spaces (pseudocysts). It is the most common and generally behaves moderately.
Tubular type: Small true tubes formed by tumor cells. Usually the least aggressive.
Solid type: Sheets of tumor cells without holes or tubes. This type tends to grow and spread faster and is graded higher.

2) By histologic grade (how aggressive it looks)

Low grade: Mostly tubular or cribriform patterns, little solid component, lower cell division rate.
Intermediate grade: Mixture of patterns with a modest solid component.
High grade: Large solid component, high cell division, necrosis, or anaplastic changes. Higher risk of recurrence and spread.

3) By anatomic origin (where it starts)

Major salivary glands: Parotid, submandibular, sublingual.
Minor salivary glands: Palate (most common oral site), lips, tongue, buccal mucosa, floor of mouth, sinuses.
Extra-salivary sites: Trachea and bronchi, lungs, lacrimal gland (orbit), breast, skin adnexal glands, vagina, prostate, and others. Behavior is broadly similar, but treatment details depend on site.

4) By biological/molecular features

MYB-pathway–activated: Many ACCs carry gene fusions that activate MYB (classically MYB-NFIB) or related MYBL1.
NOTCH-altered: Some tumors harbor NOTCH1 pathway changes and may behave more aggressively.
Ki-67 proliferation index: A higher index suggests faster growth.
These markers help confirm the diagnosis and may guide trials or targeted therapies.

5) By clinical stage (TNM)

Stage I–II: Small, localized tumors.
Stage III–IV: Larger tumors, deep invasion, bone or skull base involvement, perineural spread to major nerves/foramina, or distant metastasis (most often lung). Staging relies on detailed imaging and pathology.

Causes

Important note: For ACC, the exact cause is usually unknown. Research points to patterns and risk factors rather than single clear causes. Below are factors that are reported or plausibly linked to the biology of ACC. Each item explains what the factor is and how it may contribute.

Random DNA errors over time
Cells collect small DNA mistakes as we age. In rare cases, the right set of errors can drive a salivary gland cell to become malignant, leading to ACC.
Gene fusions activating MYB (e.g., MYB-NFIB)
A piece of one gene joins to another and turns on MYB, a growth-control gene. Persistent signaling can push cells to divide and resist death, promoting ACC.
MYBL1 activation (MYB-like pathway)
When MYBL1 acts like MYB, it can substitute as the main driver, supporting tumor growth and survival.
NOTCH pathway alterations
Changes in NOTCH1 and related genes can increase aggressiveness, invasion, and resistance to therapy in a subset of ACCs.
Epigenetic dysregulation
Chemical “tags” on DNA/histones can silence tumor-suppressor genes or activate growth pathways without changing the DNA code, nudging cells toward cancer behavior.
Perineural niche interactions
ACC cells interact with nerve sheaths and growth factors along nerves. This micro-environment supports migration and survival, explaining “perineural spread.”
Aberrant c-KIT (CD117) signaling
Many ACCs express c-KIT. While not always a true driver mutation, c-KIT-related signaling may help tumor cell survival.
Tumor microenvironment (stroma) support
Fibroblasts, immune cells, and extracellular matrix can feed growth signals, help immune escape, and ease invasion along tissue planes.
Prior head and neck radiation exposure
Radiation can damage DNA in salivary gland cells and, rarely, lead to secondary cancers years later, including ACC.
Occupational exposures (e.g., certain dusts/chemicals)
Long-term exposure to some industrial agents may raise general salivary gland cancer risk; for ACC specifically the link is not strong but is suspected.
Hormonal influences (site-dependent)
In extra-salivary sites like breast, local hormone signaling might shape tumor behavior, although a direct cause-and-effect is not established.
Chronic local irritation/inflammation
Long-lasting irritation in minor salivary glands (e.g., denture trauma) can increase cell turnover. This is a weak association and not a proven cause.
Immune escape mechanisms
Some tumors reduce immune visibility. When immune surveillance fails, early lesions can progress to overt cancer.
Stem-cell pathway imbalance
Abnormal activation of developmental pathways (e.g., Wnt, Hedgehog) may keep cells in a progenitor-like state prone to malignant growth.
Angiogenesis signaling
Pro-angiogenic factors (VEGF and others) help tumors build new blood vessels, supporting slow but persistent expansion typical of ACC.
Matrix remodeling enzymes (MMPs)
Enzymes that cut through the matrix open paths for tumor cells to move, including along nerves and into bone.
Genomic instability/repair defects
Defects in DNA repair systems allow accumulation of mutations, providing a substrate for malignant transformation.
Rare familial susceptibility
True inherited ACC syndromes are uncommon; still, background genetic susceptibility may slightly modify risk.
Lifestyle factors (weak/uncertain links)
Unlike many head and neck cancers, smoking and alcohol are not strong drivers for ACC, but general health factors can influence overall cancer risk.
Chance
Because ACC is rare and often arises without known triggers, chance plays a role—unlucky combinations of events in a single cell can start the process.

Symptoms and signs

Symptoms depend on where the tumor starts and whether it has followed nerves or spread to the lungs or bone. ACC often grows slowly, so symptoms can be subtle at first.

A firm, painless lump
A slowly enlarging mass in the palate, submandibular area, parotid region, or elsewhere. It may feel fixed because it infiltrates tissue and nerves.
Pain or tingling
As tumor cells track along nerves, they can cause burning, tingling, stabbing pain, or toothache-like discomfort.
Numbness or altered sensation
Loss of feeling in part of the face, palate, tongue, or teeth can reflect perineural spread along sensory nerves.
Facial weakness
If nerves controlling facial muscles are affected (e.g., in parotid tumors), part of the face may droop or movements may weaken.
Difficulty chewing or opening the mouth (trismus)
Invasion into muscles or joints around the jaw can restrict mouth opening and make eating hard.
Swallowing trouble (dysphagia)
Palate or tongue lesions can interfere with food flow and coordination.
Nasal blockage or nosebleeds
Sinonasal ACC can cause stuffiness on one side, chronic discharge, or nosebleeds due to local erosion.
Ear fullness or hearing changes
Eustachian tube dysfunction from nasopharyngeal spread can cause a blocked-ear feeling or conductive hearing loss.
Hoarseness or breathy voice
Tumors of the larynx/trachea or nerve involvement (recurrent laryngeal nerve) can change the voice.
Cough or shortness of breath
If ACC spreads to the lungs, it may cause a dry cough, breathlessness, or chest discomfort, often slowly progressive.
Bone pain
Bone metastasis can cause localized, deep aching pain or tenderness.
Loose teeth or ill-fitting dentures
When tumor affects the palate or alveolar bone, teeth can loosen, and dentures may stop fitting.
Facial swelling or asymmetry
As the mass grows, it can change the face outline or cause puffiness.
Headache
Perineural spread towards skull base can produce persistent, localized headache.
Fatigue and anxiety
Chronic pain, disturbed sleep, and worry about a persistent lump commonly produce tiredness and emotional stress.

Diagnostic tests

A) Physical exam

1) Comprehensive head-and-neck examination
The clinician looks and feels for lumps in the cheeks, jawline, under the tongue, and palate. They check skin, mucosa, the opening of salivary ducts, and signs of ulceration. The goal is to map the size, surface, fixation, and tenderness of the mass and to look for additional lesions.

2) Regional lymph node assessment
The neck is gently palpated along levels I–V to feel for enlarged nodes. Although ACC less commonly involves nodes than other cancers, finding firm or fixed nodes changes staging and treatment planning.

3) Cranial nerve screening
Doctor tests facial movement, facial sensation, tongue motion, palate elevation, shoulder shrug, and voice quality. Any weakness, numbness, or palate droop suggests perineural spread and pushes for dedicated imaging of nerve pathways.

4) Intraoral and dental inspection
The palate, gums, and teeth are inspected under good light. Denture fit, mucosal color, ulceration, and tooth mobility are checked. Oral findings help localize minor salivary gland primaries and plan biopsy routes.

B) Manual tests (bedside maneuvers)

5) Bimanual palpation of the floor of mouth/submandibular area
One finger inside the mouth and the other hand outside gently trap and feel a deep lump from both sides. This tells whether the mass is in the submandibular gland, duct, or floor-of-mouth minor glands and whether it feels fixed to bone.

6) Interincisal distance (mouth-opening) measurement
The clinician measures how wide the patient can open. Reduced distance indicates trismus from muscle or joint involvement and suggests deeper local invasion.

7) Sensory mapping with light touch and pinprick
Light touch (cotton) and gentle pinprick check sensation over the cheek, lips, palate, and tongue. Areas of numbness or altered sensation track the likely nerve routes of spread.

8) Facial muscle manual grading
Smiles, eye closure, eyebrow raise, and cheek puff are graded (e.g., House-Brackmann scale). Weakness suggests facial nerve involvement, common when the parotid region is affected.

C) Laboratory and pathological tests

9) Fine-needle aspiration (FNA) cytology
A thin needle pulls out cells for a cytologist to examine. In experienced hands, FNA can strongly suggest ACC by finding twin cell populations and cribriform-like fragments. It is quick, low risk, and helps plan definitive biopsy.

10) Core-needle biopsy
A larger needle retrieves a small tissue cylinder. This preserves architecture, making it easier to see tubular/cribriform/solid patterns. Core biopsy improves diagnostic confidence before major surgery or radiation.

11) Incisional (open) biopsy
When needle samples are inconclusive or location demands it (e.g., palate), a small surgical piece is taken under local anesthesia. This allows full histology with special stains and immunohistochemistry.

12) Definitive histopathology (H&E) with pattern grading
On stained slides, the pathologist identifies cribriform, tubular, or solid architecture and measures margins, perineural spread, lymphovascular invasion, and any high-grade transformation. This report is central to prognosis and treatment decisions.

13) Immunohistochemistry (IHC) panel
Common markers include c-KIT (CD117), MYB, p63, SMA, S100, and others. The pattern supports the diagnosis and helps distinguish ACC from look-alikes (e.g., polymorphous adenocarcinoma, basal cell adenocarcinoma).

14) Molecular testing for gene fusions/mutations
Assays (FISH, RT-PCR, or NGS) look for MYB-NFIB or MYBL1 fusions and for alterations in pathways like NOTCH. Molecular results confirm diagnosis in difficult cases and may guide clinical trial eligibility.

D) Electrodiagnostic tests

15) Facial nerve electromyography (EMG)
Fine needles record electrical activity from facial muscles. EMG quantifies how much the facial nerve is affected. This helps with prognosis, surgical planning (e.g., nerve graft needs), and tracking recovery after treatment.

16) Trigeminal sensory nerve testing
When numbness suggests spread along branches of the trigeminal nerve, targeted sensory tests (quantitative sensory testing or nerve conduction in select centers) can document deficits and direct imaging to skull-base foramina.

E) Imaging tests

17) MRI with contrast of the primary site and skull base
MRI is the best test for perineural spread. It shows tumor extent in soft tissues, along nerves, into masticator space, parapharyngeal space, or towards the skull base. Contrast highlights tumor and inflamed nerves; fat-suppressed sequences help see small tracks.

18) CT scan (maxillofacial/neck) for bone and surgical planning
CT shows bone erosion, calcification, and the relationship to teeth and jaw. It complements MRI by giving fine bony detail that matters for margins and reconstruction.

19) Chest CT for distant spread
Because ACC commonly spreads to the lungs, a dedicated chest CT is standard at baseline and during follow-up. It can reveal tiny nodules that a chest X-ray misses.

20) PET-CT (or PET-MRI) in selected cases
PET helps stage widely, looks for distant disease, and can assess active vs scar tissue. Sensitivity varies with ACC, so PET is used together with site MRI and chest CT to get the full picture.

Non-pharmacological treatments

Pre-surgery “prehab” program (strength + breathing + nutrition)
Description: 2–4 weeks of guided exercises (walking, light resistance bands), breathing drills, and diet upgrade (adequate protein, hydration).
Purpose: Improve fitness before surgery or radiotherapy.
Mechanism: Builds cardiorespiratory reserve; reduces postoperative fatigue; supports wound healing with better protein status.
Benefits: Shorter hospital stays, easier recovery, fewer complications.
Post-operative neck and jaw physiotherapy
Description: Gentle, progressive range-of-motion for neck, shoulder, jaw (trismus prevention), with scar massage once cleared.
Purpose: Restore function after parotidectomy, mandibulectomy, or neck dissection.
Mechanism: Prevents stiffness, adhesions, and muscle imbalance; supports lymph flow.
Benefits: Better chewing, speech, and neck mobility; less pain.
Swallowing therapy (speech-language pathology)
Description: Personalized swallow exercises, safe-swallow strategies, texture modifications.
Purpose: Protect airway and nutrition when tongue, floor of mouth, or pharynx are involved or after radiation.
Mechanism: Strengthens suprahyoid and pharyngeal muscles; compensatory techniques reduce aspiration risk.
Benefits: Fewer choking events; better calorie/protein intake; improved quality of life.
Lymphedema therapy for head & neck
Description: Manual lymph drainage, compression (as tolerated), posture training, home self-care.
Purpose: Reduce swelling after neck dissection/radiation.
Mechanism: Stimulates collateral lymph flow and reduces tissue fibrosis.
Benefits: Smaller neck/facial swelling, improved comfort and appearance.
Facial nerve rehabilitation
Description: Guided facial muscle re-education, biofeedback; eye-care routines if incomplete eyelid closure.
Purpose: Address weakness or synkinesis after nerve sacrifice or injury.
Mechanism: Re-trains motor units and normalizes aberrant patterns.
Benefits: Better symmetry, eye protection, confidence.
Pain neuroscience education + graded activity
Description: Coaching to understand cancer-related pain and safely resume movement with pacing.
Purpose: Cut fear-avoidance and disability.
Mechanism: Reduces central sensitization and catastrophizing.
Benefits: Less pain interference, more daily function.
Mindfulness-based stress reduction (MBSR)
Description: Eight-week curriculum or app-guided practice (10–20 minutes/day).
Purpose: Ease anxiety, insomnia, and treatment stress.
Mechanism: Down-regulates HPA axis and sympathetic arousal.
Benefits: Better sleep, mood, and coping.
Cognitive-behavioral therapy (CBT) for cancer-related distress
Description: Brief, structured sessions focusing on thoughts, behaviors, and problem-solving.
Purpose: Manage uncertainty, scanning anxiety, and body-image changes.
Mechanism: Reframes maladaptive beliefs; builds practical skills.
Benefits: Lower depression/anxiety, improved adherence.
Acceptance & commitment therapy (ACT)
Description: Values-guided actions despite difficult emotions.
Purpose: Enhance life quality when there is chronic disease.
Mechanism: Psychological flexibility.
Benefits: More participation in meaningful activities.
Guided imagery and breathing retraining
Description: 4–7–8 breathing, diaphragmatic breathing, visualization.
Purpose: Reduce procedure anxiety and improve sleep.
Mechanism: Vagal stimulation lowers heart rate and cortisol.
Benefits: Calmer mood, better rest.
Medical nutrition therapy (with oncology dietitian)
Description: Personalized plan with 1.2–1.5 g/kg/day protein (as appropriate), fiber, phytonutrient-rich foods; troubleshoot dry mouth, taste change.
Purpose: Maintain weight and muscle; support healing.
Mechanism: Adequate amino acids, micronutrients, and energy balance.
Benefits: Fewer treatment breaks, faster recovery.
Saliva and oral-care program
Description: Scheduled hydration; saliva substitutes/xylitol gum; fluoride trays; alcohol-free mouthwash; humidifier.
Purpose: Counter dry mouth (xerostomia), mucositis, dental decay from RT.
Mechanism: Moisture replacement and enamel protection.
Benefits: Less caries, better taste and comfort.
Voice and communication coaching
Description: Techniques to optimize resonance, pacing, and assistive tech if needed.
Purpose: Restore communication after oral/sinonasal/airway surgery.
Mechanism: Compensatory strategies and muscle training.
Benefits: Clearer speech, social participation.
Fatigue management (energy conservation + graded exercise)
Description: Plan activity “sandwiches,” short walks, light resistance 2–3x/week.
Purpose: Tackle cancer-related fatigue.
Mechanism: Improves mitochondrial efficiency and sleep quality.
Benefits: More stamina, less “crash.”
Sleep hygiene and insomnia coaching
Description: Consistent schedule, screen curfew, dark cool room, stimulus control.
Purpose: Improve non-pharmacologic sleep.
Mechanism: Resets circadian and conditioned arousal.
Benefits: Better energy, mood, pain tolerance.
Sun/skin care during radiation
Description: Gentle cleansers, fragrance-free moisturizers, loose clothing, SPF on non-treated areas.
Purpose: Reduce radiation dermatitis.
Mechanism: Protects skin barrier and limits UV damage.
Benefits: Fewer interruptions to RT.
Dental oncology co-management
Description: Pre-RT dental clearance; extractions (if needed) before RT; lifelong fluoride and hygiene plan.
Purpose: Prevent osteoradionecrosis and caries.
Mechanism: Reduces infection risk and jaw complications.
Benefits: Long-term oral health.
Smoking and alcohol counseling (if applicable)
Description: Motivational support, nicotine replacement, or referral.
Purpose: Lower complications and second-cancer risk.
Mechanism: Removes carcinogen exposure and improves healing.
Benefits: Better outcomes and energy.
Occupational therapy for daily-life adaptations
Description: Eating aids, mouth-moistening strategies, work simplification.
Purpose: Maintain independence during treatment.
Mechanism: Task modification and ergonomic support.
Benefits: Less frustration, better function.
Palliative care (early integration)
Description: Symptom-focused team works alongside oncology from diagnosis in advanced cases.
Purpose: Optimize comfort and decision-making.
Mechanism: Multidimensional pain, mood, and spiritual care.
Benefits: Better quality of life and satisfaction.
Education on red-flag symptoms & follow-up schedule
Description: Written plan for what to watch and when to call.
Purpose: Detect recurrence early.
Mechanism: Informed self-monitoring.
Benefits: Timely care.
Financial navigation & social work support
Description: Help with insurance, leave, and travel to specialized centers (proton/C-ion).
Purpose: Reduce treatment barriers.
Mechanism: Resource linkage.
Benefits: More complete care.
Peer support / survivorship groups
Description: Online or local ACC communities.
Purpose: Share coping strategies and hope.
Mechanism: Normalization and practical tips.
Benefits: Lower isolation.
Gentle yoga or tai chi (as cleared)
Description: Low-impact movement plus breath.
Purpose: Ease stiffness and anxiety.
Mechanism: Parasympathetic activation and flexibility.
Benefits: Better balance and calm.
Evidence-informed complementary care (e.g., acupuncture for xerostomia or nausea)
Description: Performed by licensed clinicians, coordinated with oncology.
Purpose: Symptom relief.
Mechanism: Neuromodulation and salivary reflex effects.
Benefits: Improved comfort; reduced antiemetic needs.

Drug treatments

Important safety note: The following is general educational information. Do not start/stop or change any medicine without your oncology team. Doses are typical study doses; your dose may differ based on health, labs, interactions, and side-effects.

Lenvatinib (VEGFR/FGFR TKI)
Typical dose/time: 24 mg orally once daily, continuous.
Purpose: Slow tumor growth in recurrent/metastatic ACC.
Mechanism: Blocks VEGF/FGF-driven tumor blood supply and signaling.
Evidence: Phase II: ~16% partial response; majority achieve disease stabilization; median PFS ~17 months in one study cohort.
Side effects: High blood pressure, fatigue, proteinuria, hand-foot syndrome; dose reductions common. PMCPubMed
Axitinib (VEGFR TKI)
Typical dose/time: 5 mg orally twice daily; titrate as tolerated.
Purpose: Delay progression in advanced ACC.
Mechanism: Potent VEGFR-1/2/3 inhibition.
Evidence: First randomized ACC trial: axitinib improved 6-month PFS vs observation; combinations with avelumab show ORR ~14–18% and 6-month PFS ~57%.
Side effects: Hypertension, diarrhea, fatigue, hand-foot, hoarseness. AACR JournalsPubMed+1ASCO Publications
Pazopanib (VEGFR TKI)
Typical dose: 800 mg orally once daily.
Purpose/mechanism: Similar anti-angiogenic strategy; used off-label when other TKIs unsuitable.
Evidence: Small series suggest disease stabilization more than shrinkage.
Side effects: Liver enzyme rise, hypertension, diarrhea.
Sunitinib or Sorafenib (multi-kinase TKIs)
Typical dose: Sunitinib 37.5–50 mg daily (schedule varies); Sorafenib 400 mg twice daily.
Purpose: Anti-angiogenic control when lenvatinib/axitinib not options.
Evidence: Case series; modest activity, mostly stable disease.
Side effects: Fatigue, hand-foot, hypertension, mucositis.
Regorafenib (multi-kinase TKI)
Typical dose: 160 mg daily, 3 weeks on / 1 week off.
Purpose: Later-line anti-angiogenic option.
Evidence: Limited ACC data; used by extrapolation.
Side effects: Hand-foot, fatigue, hypertension.
Cisplatin + 5-FU (or CAP: Cyclophosphamide-Doxorubicin-Cisplatin)
Typical dose: Regimen-dependent every 3–4 weeks.
Purpose: Cytotoxic chemotherapy for symptom control when tumor is fast-growing or causing pressure symptoms.
Mechanism: DNA damage and cell-cycle arrest.
Evidence: Responses occur but are usually short-lived; used palliatively.
Side effects: Nausea, low blood counts, neuropathy, mucositis.
Taxanes (Docetaxel or Paclitaxel), alone or with platinum
Typical dose: Docetaxel 60–75 mg/m² q3w; Paclitaxel 80 mg/m² weekly.
Purpose: Cytotoxic option for symptomatic disease.
Mechanism: Microtubule stabilization.
Evidence: Modest responses or disease control in small series.
Side effects: Neuropathy, myelosuppression, alopecia.
Gemcitabine-based regimens (± cisplatin)
Purpose/mechanism: Nucleoside analog; can shrink fast-growing lesions in selected cases.
Evidence: Case reports/series; not a standard backbone.
Side effects: Fatigue, low counts.
Vinorelbine (± cisplatin)
Purpose: Another cytotoxic option when others are exhausted.
Mechanism: Vinca alkaloid; inhibits microtubules.
Evidence: Small studies suggest stabilization.
Side effects: Neutropenia, neuropathy.
Immunotherapy: Pembrolizumab (PD-1 inhibitor)
Typical dose: 200 mg IV every 3 weeks (or 400 mg q6w).
Purpose: Stimulate immune attack; may help a subset.
Evidence: Trials show low objective response rate (~4–5% overall; many get stable disease), with better local responses in irradiated fields; combinations with RT explored.
Side effects: Immune-related (thyroiditis, pneumonitis, colitis). ScienceDirectPMC
Nivolumab (PD-1 inhibitor)
Use: Similar rationale to pembrolizumab; evidence limited to small studies/series with rare responses; sometimes durable when they occur.
Side effects: Immune-related events.
Avelumab (PD-L1 inhibitor) + Axitinib
Purpose: Dual immuno-antiangiogenic strategy; may modestly increase responses vs TKI alone.
Evidence: Phase II ORR ~14–18%; median PFS ~7 months.
Side effects: Fatigue, hypertension, diarrhea; immune AEs. PubMedASCO Publications
Larotrectinib or Entrectinib (NTRK inhibitors)
Use: Only for tumors with NTRK fusions (rare in ACC).
Mechanism: Blocks TRK signaling driving tumor growth.
Evidence: Tumor-agnostic approvals; individual ACC cases respond.
Side effects: Dizziness, fatigue, weight gain. PMC
NOTCH pathway inhibitors (clinical trials; e.g., AL101/AL102)
Use: For tumors with activating NOTCH1 mutations (subset with worse prognosis).
Evidence: Early-phase data and retrospective signals; access mainly via trials.
Side effects: GI upset, fatigue, electrolyte changes. PMCFrontiers
Targeted therapy via precision oncology (trial-matched)
Use: If genomic testing reveals actionable alterations beyond MYB (e.g., rare HER2, PIK3CA, or others), matched trials may be available.
Evidence: Case-by-case; discuss at a molecular tumor board.
Side effects: Vary by agent.

Dietary “molecular/supportive” supplements

Reality check: No supplement is proven to treat ACC. The points below are adjuncts for general cancer wellness and may interact with treatments. Always clear with your oncology team.

Medical nutrition shakes / whey isolate – Aim ~20–30 g high-quality protein per serving to reach ~1.2–1.5 g/kg/day total; supports wound healing and lean mass.
Vitamin D3 – If deficient, clinicians often replete to reach 25-OH D in the sufficient range; supports bone, muscle, and immunity.
Omega-3 (EPA/DHA) – ~1–2 g/day combined EPA/DHA can help maintain weight and may reduce inflammation; monitor with anticoagulants.
Probiotics (e.g., Lactobacillus/Bifidobacterium blends) – May help with antibiotic-related diarrhea or RT-induced GI changes; discuss strain and timing.
Oral L-glutamine – Sometimes used for mucositis support; evidence mixed; ask before use if on certain chemo.
Green tea extract (EGCG) – Antioxidant; avoid near radiation sessions and some chemo due to theoretical interference; if used, low-dose and separated by days not on RT.
Curcumin (turmeric extract) – Anti-inflammatory; may inhibit CYP enzymes; review interactions carefully.
Ginger extract – Helpful for nausea; can be combined with standard antiemetics; watch with anticoagulants.
Selenium (low-dose only if deficient) – Over-supplementation is harmful; use only under clinician guidance.
Melatonin (2–5 mg at bedtime) – Can improve sleep onset; check for interactions and daytime grogginess.

(These reflect general oncology nutrition and supportive care principles rather than ACC-specific evidence.)

Immunity-booster / regenerative / stem-cell” drugs

There are no approved “stem-cell drugs” or over-the-counter “immunity boosters” that treat ACC. Be cautious with unregulated products.
Clinically used immune-modulating drugs (like pembrolizumab or nivolumab) are prescription anticancer medicines with specific indications; response rates in ACC are low overall, though occasional durable responses occur. Combined approaches (e.g., with radiation or VEGFR TKIs) are being tested. ScienceDirectPMCPubMed
Adoptive cell therapies / cancer vaccines for ACC are investigational and available mainly in clinical trials.
Hematopoietic stem-cell transplants are not standard for ACC.
If you are interested in immune-based options, ask for clinical-trial matching based on your tumor’s genetics and PD-L1/TMB profile.

Surgeries

Wide local excision / parotidectomy / submandibular gland excision
What: Remove the gland and tumor with an adequate margin; sometimes needing sacrifice/reconstruction of involved nerves.
Why: Best chance for cure when disease is localized and resectable; sets up adjuvant RT to sterilize microscopic disease. PMC
Skull-base / perineural tract surgery (select cases)
What: Specialized approaches to remove tumor tracking along cranial nerves toward the skull base.
Why: Achieve local control when imaging shows perineural spread that can be safely accessed; often followed by high-precision RT. PMCJournal of Nuclear Medicine
Sinonasal endoscopic or open resection
What: Removal of tumors in nasal cavity or sinuses, sometimes combined with craniofacial approaches.
Why: Achieve negative margins in anatomically tight spaces; often teamed with proton/carbon-ion RT. PMC
Tracheal/bronchial segmental resection (for airway ACC)
What: Remove a short segment of trachea/bronchus and reconnect ends.
Why: Restore airway patency and control local disease in primary tracheobronchial ACC.
Selective/therapeutic neck dissection (case-by-case)
What: Remove lymph nodes at risk.
Why: Nodal spread is less common in ACC than in other head-neck cancers, but surgery may be indicated if nodes are involved clinically/radiologically. PMC
IMRT (photon) – Standard modern RT that shapes dose around nerves and brain; routine adjuvant after high-risk surgery or definitive when unresectable. PMC
Proton therapy – Can reduce dose to healthy tissues; growing evidence shows excellent local control in head-neck ACC; helpful for skull-base/sinonasal sites. PMCPubMed
Carbon-ion therapy – High linear-energy transfer; available in select countries; promising local control for salivary ACC including when surgery is not feasible. Access depends on geography and referral. PMC+1

Prevention & self-care pointers

Don’t smoke; limit alcohol. Lowers overall head-neck cancer and treatment complications.
Protect dental health before and after RT: fluoride trays, diligent hygiene, regular dental care.
Nutrition first: Adequate protein, fruits/vegetables, hydration.
Vaccinations as advised (e.g., influenza); coordinate with oncology.
Exercise most days as tolerated; even short walks help.
Sun/skin care during RT; gentle skin routine.
Mouth care routine to prevent mucositis and infections.
Avoid unproven “cancer cures.” Discuss supplements with your team to avoid interactions.
Know your follow-up plan and keep imaging/labs on schedule (ACC can recur late).
Seek specialist centers for complex skull-base or sinonasal cases (consider proton/carbon-ion referral when appropriate). PMC

When to see doctors

New or growing lump near jaw, under tongue, inside cheek, palate, or nasal cavity.
Facial weakness, drooping, or twitching; numbness or pain along the jaw, teeth, ear, or face (possible perineural spread).
Trouble chewing, swallowing, speaking, persistent hoarseness, or nasal blockage/bleeding.
After treatment: any new pain, lumps, cough/shortness of breath, bone pain, or neurological symptoms.
Report these promptly; ACC can recur after many years, so long-term follow-up is essential. Journal of Nuclear Medicine

What to eat & “what to avoid

What to eat:

Protein-rich foods (eggs, fish, poultry, tofu, Greek yogurt, lentils) at each meal.
Soft, moist textures if chewing/swallowing is hard (soups, smoothies, stews, oatmeal, mashed vegetables with olive oil).
Colorful fruits/vegetables for fiber and micronutrients; include healthy fats (olive oil, avocado, nuts if tolerated).
Plenty of fluids; consider oral rehydration solutions on tough days.

What to avoid (or limit):

Very spicy, acidic, or sharp-edged foods if mouth is sore.
Alcohol and tobacco.
Highly sugary snacks sipping all day (cavity risk with dry mouth).
Large high-fat meals right before RT (can worsen nausea for some).
Supplements with strong antioxidant effects taken right around radiation sessions (theoretical interference)—coordinate timing with your team.

FAQs

Is ACC curable?
Sometimes—especially when found early and completely removed, followed by appropriate radiotherapy. Because it can return late, long-term follow-up is vital. PMC
Why is radiation recommended after “successful” surgery?
Because ACC often tracks along nerves, microscopic cells can remain; adjuvant RT lowers local-recurrence risk. Frontiers
What makes ACC different from other salivary cancers?
It grows along nerves and can recur late; it also has characteristic MYB family fusions and sometimes NOTCH changes. Lippincott JournalsFrontiers
Do lymph nodes usually get involved?
Less often than in many head-neck cancers; node surgery is individualized. PMC
If my tumor can’t be fully removed, what then?
Definitive high-precision RT (IMRT, proton, sometimes carbon-ion) is a standard approach. PMC+1
Which systemic drugs work best?
VEGFR TKIs (lenvatinib, axitinib) have the most consistent disease control; chemo can help symptoms; immunotherapy helps a minority. PMCAACR JournalsScienceDirect
Will immunotherapy help me?
Overall response rates are low; some patients stabilize for months. Discuss trials and combination strategies. ScienceDirectPMC
Are protons or carbon ions better than regular radiation?
They can better spare normal tissues in complex areas; outcome advantages depend on case details and center expertise. PMC+1
What genes should be tested?
Broad NGS to look for MYB/MYBL1 fusions (diagnostic), NOTCH1 status, and rare actionable fusions (e.g., NTRK) for trial matching. Lippincott JournalsFrontiers
Can ACC be prevented?
No specific prevention is known; healthy living and avoiding tobacco help overall health and treatment tolerance.
How long will I be followed?
Often for life, with imaging tailored to your risk and symptoms, because late recurrences can occur. ScienceDirect
Does radiation damage my teeth or jaw?
It can—hence the dental plan (fluoride trays, hygiene, pre-RT dental work) to reduce risk of osteoradionecrosis and cavities. ScienceDirect
I read about a “complete response” with personalized immunotherapy. Is that common?
Such reports exist but are rare; they highlight the value of trials and individualized care rather than a predictable outcome. MDPI
Should I travel to a proton or carbon-ion center?
Consider referral for skull-base/sinonasal or previously irradiated cases; discuss logistics and expected benefit with your team. PMC+1
What’s the single most important thing I can do?
Stick closely to your care plan, keep up with follow-up imaging, and report new symptoms early.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 08, 2025.

PDF Documents For This Disease Condition

References

SaveSavedRemoved 0